<DOC>
	<DOCNO>NCT00032045</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may make body build immune response kill tumor cell . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining vaccine therapy monoclonal antibody may cause strong immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness combine vaccine therapy monoclonal antibody therapy treat patient stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Monoclonal Antibody Therapy Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical response patient stage IV melanoma treat anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody combine gp100:209-217 gp100:280-288 peptide emulsify Montanide ISA-51 . - Determine safety adverse event profile regimen patient . - Determine improve immunologic response patient treat regimen . OUTLINE : This open-label study . Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV 90 minute immediately follow gp100:209-217 gp100:280-288 peptide emulsify Montanide ISA-51 subcutaneously day 1 , 22 , 43 , 64 . Treatment repeat every 12 week absence disease progression unacceptable toxicity . Patients follow 3 week , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 68 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV melanoma Mucosal ocular melanoma allow Clinically evaluable disease HLAA*0201 positive PATIENT CHARACTERISTICS : Age : 16 Performance status : Karnofsky 60100 % Life expectancy : At least 6 month Hematopoietic : WBC least 2,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hematocrit least 30 % Hepatic : AST great 3 time upper limit normal ( ULN ) Bilirubin great ULN ( less 3.0 mg/dL patient Gilbert 's syndrome ) Hepatitis B surface antigen negative Hepatitis C antibody nonreactive Renal : Creatinine le 2.0 mg/dL Immunologic : Antinuclear antibody negative Thyroglobulin antibody normal Rheumatoid factor normal HIV negative No prior autoimmune disease ( include uveitis autoimmune inflammatory eye disease ) No active infection No hypersensitivity Montanide ISA51 Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix No underlying medical condition would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy melanoma recover No prior gp100 peptides No prior anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody Chemotherapy : At least 3 week since prior chemotherapy melanoma recover No concurrent chemotherapy Endocrine therapy : At least 3 week since prior hormonal therapy melanoma recover At least 4 week since prior systemic topical corticosteroid No concurrent topical systemic corticosteroid Radiotherapy : At least 3 week since prior radiotherapy melanoma recover Surgery : Not specify Other : No concurrent immunosuppressive agent ( e.g. , cyclosporine analog )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>